Modified Huanglian Wendan Decoction for Metabolic Syndrome
Summary
This randomized controlled clinical study aims to evaluate the effect of Modified Huanglian Wendan Decoction on oxidative stress in patients with metabolic syndrome. A total of 180 patients with metabolic syndrome from The First Affiliated Hospital of Heilongjiang University of Chinese Medicine will be assigned to a control group or an observation group at a 1:1 ratio. Participants in both groups will receive lifestyle intervention and standard therapy, including antihypertensive, hypoglycemic, and lipid-lowering treatment. Participants in the observation group will additionally receive Modified Huanglian Wendan Decoction for 3 months. The study will compare changes in oxidative stress indicators, obesity-related parameters, blood pressure, glucose and lipid metabolism, and insulin resistance before and after treatment.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Modified Huanglian Wendan Decoction | Unknown | 150 ml | Oral |
| Background | Atorvastatin | Small molecule | 10 mg | Oral |
| Background | Metformin | Small molecule | 0.5 g | Oral |
| Background | Valsartan | Small molecule | 80 mg | Oral |